Oculis Holding AG (NASDAQ: OCS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 57.17M | Perf Week | -3.98% |
| Market Cap | 579.70M | Forward P/E | - | EPS next Y | -2.04 | Insider Trans | - | Shs Float | 37.03M | Perf Month | -25.28% |
| Enterprise Value | 581.70M | PEG | - | EPS next Q | -0.60 | Inst Own | 35.94% | Short Float | 4.02% | Perf Quarter | -9.63% |
| Income | -114.00M | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 3.10 | Perf Half Y | -60.03% |
| Sales | 0.00 | P/B | 2.14 | EPS next Y | -10.15% | ROA | -31.82% | Short Interest | 1.49M | Perf YTD | -49.22% |
| Book/sh | 4.74 | P/C | - | EPS next 5Y | - | ROE | -42.92% | 52W High | 34.48 -70.59% | Perf Year | -41.72% |
| Cash/sh | 0.00 | P/FCF | - | EPS past 3/5Y | - | ROIC | -38.94% | 52W Low | 9.65 5.08% | Perf 3Y | -17.56% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 35.21% | Volatility | 5.00% 4.39% | Perf 5Y | 4.32% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | 27.80% | Oper. Margin | -35874.24% | ATR (14) | 0.57 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.35 | Sales Y/Y TTM | - | Profit Margin | -32780.20% | RSI (14) | 25.51 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.35 | EPS Q/Q | 66.10% | SMA20 | -13.27% | Beta | 0.25 | Target Price | 38.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | -15.89% | Rel Volume | 1.38 | Prev Close | 9.98 |
| Employees | 60 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -50.92% | Avg Volume | 297.57K | Price | 10.14 |
| IPO Date | May 18, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 59.02% 73.95% | Net Debt/EBITDA | -0.03 | Volume | 411,951 | Change | 1.60% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-01-26 | Reiterated | Robert W. Baird | $38 | |
| Jun-01-26 | Reiterated | Guggenheim | Buy | |
| Jun-01-26 | Reiterated | Needham | Buy | $38 |
| Jun-01-26 | Reiterated | HC Wainwright & Co. | Buy | $26 |
| May-20-26 | Initiated | Guggenheim | Buy | |
| May-12-26 | Reiterated | HC Wainwright & Co. | Buy | $36 |
| Mar-04-26 | Reiterated | Stifel Nicolaus | $40 | |
| Dec-19-25 | Reiterated | Stifel Nicolaus | $40 | |
| Oct-08-25 | Reiterated | Chardan Capital | Buy | |
| Oct-07-25 | Reiterated | HC Wainwright & Co. | Buy | $33 → $36 |
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 1 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 59 | 0 | — | — | — | |
| Gross Profit | 0 | -58 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 30 | 25 | 16 | — | — | — | |
| Research and Development | 66 | 59 | 33 | — | — | — | |
| Other Operating Expense | -1 | -59 | 41 | — | — | — | |
| Operating Income | -95 | -83 | -90 | — | — | — | |
| Interest Expense | 1 | 1 | 2 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -18 | -14 | -7 | — | — | — | |
| Net Income Before Taxes | -114 | -98 | -99 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -114 | -98 | -99 | — | — | — | |
| Net Income From Continuing Operations | -114 | -98 | -99 | — | — | — | |
| Net Income | -114 | -98 | -99 | — | — | — | |
| EPS (Recurring) | -2.18 | -2.41 | -3.31 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.18 | -2.41 | -3.31 | — | — | — | |
| EPS (Diluted) | -2.18 | -2.41 | -3.31 | — | — | — | |
| EBITDA | -112 | -97 | -97 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | 680.00 | — | — | — | — | |
| Gross Margin | — | -5,800.00 | — | — | — | — | |
| Operating Margin | — | -8,300.00 | — | — | — | — | |
| Net Margin | — | -9,800.00 | — | — | — | — | |
| Shares Outstanding | 52 | 40 | 30 | — | — | — | |
| Market Capitalization | 1,038 | 680 | 337 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |